Goldman Sachs
TCRT icon

Goldman Sachs’s Alaunos Therapeutics TCRT Stock Holding History

Goldman Sachs’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-519
Closed -$647K – 7326
2015
Q4 		$647K Buy
+519
New +$858K ﹤0.01% 4691
2015
Q3 		– Sell
-2,001
Closed -$3.6M – 7487
2015
Q2 		$3.6M Sell
2,001
-2,498
-56% -$3.88M ﹤0.01% 3254
2015
Q1 		$7.27M Buy
4,499
+4,119
+1,084% +$6.1M ﹤0.01% 2557
2014
Q4 		$289K Buy
+380
New +$202K ﹤0.01% 5825

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Goldman Sachs's TCRT Position: Q1 2024 in Review

Goldman Sachs sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 68 shares — an estimated $718 sold.

Goldman Sachs first reported a position in TCRT in Q2 2013 and held it in 43 quarters. The position peaked at $6.21M in Q2 2020. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Goldman Sachs reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Goldman Sachs sold 68 Alaunos Therapeutics shares in Q1 2024, an estimated $718.
  • Goldman Sachs first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 43 quarters.
  • Goldman Sachs's Alaunos Therapeutics position peaked at $6.21M in Q2 2020.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Goldman Sachs's 13F filing for Q1 2024, filed 15 May 2024.